# Asymmetric dearomatization of 2-nitrobenzofurans by

### organocatalyzed one-step Michael addition to access

## 3,3'-disubstituted oxindoles

Zhen-Zhen Ge,<sup>a,d,§</sup> Lei Yang,<sup>a,d,§</sup> Yong You,<sup>b</sup> Zhen-Hua Wang,<sup>b</sup> Ke-Xin Xie,<sup>c</sup> Ming-Qiang Zhou,<sup>a</sup> Jian-Qiang Zhao,<sup>b\*</sup> and Wei-Cheng Yuan<sup>a,b\*</sup>

<sup>a</sup>National Engineering Research Center of Chiral Drugs, Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, Chengdu, 610041, China.
<sup>b</sup>Institute for Advanced Study, Chengdu University, Chengdu 610106, China.
<sup>c</sup>Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China
<sup>d</sup>University of Chinese Academy of Sciences, Beijing, 100049, China

yuanwc@cioc.ac.cn zhaojianqiang@cdu.edu.cn

# **Supporting Information**

# **Table of Contents**

1.	General experimental information
2.	General experimental procedures for synthesis of 2-nitrobenzofuransS1
3.	General experimental procedures for synthesis of 3-pyrrolyl-oxindolesS1
4.	General experimental procedures for asymmetric synthesis of compounds 3S1
5.	General experimental procedures for asymmetric synthesis of compounds 5
6.	Scale-up experiment
7.	X-Ray crystal data for compounds <b>3d</b>
8.	Proposed activation mode for the reaction of 3-monosubstituted oxindoles and
	2-nitrobenzofurans
9.	General experimental procedures for in vitro cytotoxicity assay
10.	<sup>1</sup> H, <sup>13</sup> C NMR, and HPLC spectra for compounds <b>3</b> and <b>5</b>

#### 1. General experimental information

Reagents were purchased from commercial sources and were used as received unless mentioned otherwise. Reactions were monitored by TLC. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded in CDCl<sub>3</sub>. <sup>1</sup>H NMR chemical shifts are reported in ppm relative to tetramethylsilane (TMS) with the solvent resonance employed as the internal standard (CDCl<sub>3</sub> at 7.26 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz) and integration. <sup>13</sup>C NMR chemical shifts are reported in ppm from tetramethylsilane (TMS) with the solvent resonance as the internal standard (CDCl<sub>3</sub> at 77.20 ppm). Melting points were recorded on a melting point apparatus.

General experimental procedures for synthesis of 2-nitrobenzofurans. 2-Nitrobenzofurans
 1 were synthesized following known procedure.<sup>1,2</sup>



A solution of **S1** (1.0 equiv) in MeOH (0.1 M) was slowly added NaBH<sub>4</sub> (2.0 equiv) at 0 °C. Then the reaction was warmed to room temperature for completion (monitored by TLC). After quenched with water, the mixture was concentrated by rotary evaporation to remove MeOH, extracted with EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated by rotary evaporation to afford the crude **S2**. To a 100 mL flask were added crude **S2**, Bu<sub>4</sub>NI (2.5 equiv), NEt<sub>3</sub> (2.0 equiv), PhI(OAc)<sub>2</sub> (3.0 equiv) and acetonitrile (0.1 M). The mixture was stirred at 35 °C for 1-2 h. Upon completion as shown by TLC, the reaction mixture was washed with saturated Na<sub>2</sub>S2O<sub>3</sub> and extracted using EtOAc The organic layer was dried over MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE/EtOAc = 20/1) to afford the desired product **1**.

**3.** General experimental procedures for synthesis of 3-pyrrolyl-oxindoles. Compounds 2 were synthesized following known procedure.<sup>3</sup>



To isatin **S1** (10 mmol), hydroxyproline (10 mmol), and iodine (200 mg) was added ethanol (20 mL) and the mixture was heated under reflux for 1 h. Then the mixture was diluted with water (6 mL), extracted with  $CH_2Cl_2$  (2×50mL), and the extract was washed with  $Na_2S_2O_3$  solution (10%, 50 mL), saturated  $Na_2CO_3$  (50 mL), and dried ( $Na_2SO_4$ ). Pure product **2** was isolated by silica gel column chromatography eluting with ethyl acetate/hexane (30/70).

### **Reference:**

- (1) S.-C. Lu, P.-R. Zheng and G. Liu, J. Org. Chem., 2012, 77, 7711.
- (2) Q. Cheng, H.-J. Zhang, W.-J. Yue and S.-L. You, Chem., 2017, 3, 428.
- (3) B.-D. Cui, Y. You, J. -Q. Zhao, J. Zuo, Z. -J. Wu, X. -Y. Xu, X. -M. Zhang and W. -C. Yuan, *Chem. Commun.*, 2015, **51**, 757.

#### 4. General experimental procedures for asymmetric synthesis of compounds 3

To a solution of catalyst **D** (7.1 mg, 0.01 mmol, 10 mol %) and 2-nitrobenzofurans **1** (0.12 mmol) in xylene (1.0 mL) was added 3-pyrrolyl-oxindoles **2** (0.1 mmol) at -20 °C. Then the

mixture was stirred continuously for specific time at -20 °C. After completion, the reaction mixture was directly purified by flash chromatography on silica gel (petroleum ether/ethyl acetate =  $3:1 \sim 6:1$ ) to give the corresponding products **3**.



(S)-1-methyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-(1*H*-pyrrol-1-yl)indolin-2-one (3a). Light yellow solid; 37.4 mg, 99% yield; >20:1 dr, 96% ee;  $[\alpha]_D^{20} = -52.7$  (*c* 1.83, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 172.8-173.9 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 21.34$  min,  $t_{minor} = 14.15$  min); <sup>1</sup>H NMR

(300 MHz, CDCl<sub>3</sub>)  $\delta$  3.23 (s, 3H), 4.86-4.95 (m, 1H), 5.48 (d, J = 1.9 Hz, 1H), 5.91-6.05 (m, 1H), 6.27 (t, J = 2.3 Hz, 2H), 6.32-6.44 (m, 1H), 6.85-6.96 (m, 2H), 6.95-7.02 (m, 2H), 7.04 (t, J = 2.2 Hz, 2H), 7.28-7.37 (m, 1H), 7.40-7.48 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.7, 56.0, 66.1, 106.2, 109.3, 109.6, 110.3, 119.4, 120.4, 122.6, 123.2, 123.4, 125.6, 126.0, 130.8, 131.4, 144.0, 159.1, 171.8; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>17</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 398.1111; found: 398.1100.



(S)-3-((2S,3R)-5-fluoro-2-nitro-2,3-dihydrobenzofuran-3-yl)-1-methyl-3-(1 H-pyrrol-1-yl)indolin-2-one (3b). Light yellow solid; 36.1 mg, 92% yield; >20:1 dr, 95% ee;  $[\alpha]_D^{20} = -100.9$  (*c* 1.63, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 93.5-94.7 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 26.61$  min,  $t_{minor} = 15.61$  min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.25 (s, 3H), 4.83-4.94 (m,

1H), 5.46 (d, J = 1.9 Hz, 1H), 5.58-5.69 (m, 1H), 6.29 (t, J = 2.2 Hz, 2H), 6.42-6.55 (m, 1H), 6.91-6.99 (m, 2H), 6.99-7.07 (m, 4H), 7.42-7.50 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl3)  $\delta$  26.7, 56.2 (J = 2.1 Hz), 65.8, 106.6, 109.4, 109.9, 110.8 (J = 8.5 Hz), 113.0 (J = 26.3 Hz), 117.4 (J = 24.6 Hz), 119.3, 122.0, 122.2, 123.3, 125.9, 131.6, 144.0, 156.2 (J = 168.6 Hz), 160.4, 171.6; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub>FN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 416.1017; found: 416.1023.



(S)-3-((2S,3R)-7-fluoro-2-nitro-2,3-dihydrobenzofuran-3-yl)-1-methyl-3-( 1H-pyrrol-1-yl)indolin-2-one (3c). Light yellow solid; 35.7 mg, 91% yield; >20:1 dr, 88% ee;  $[\alpha]_D^{20} = -68.6$  (*c* 1.45, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 176.3-177.5 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (90/10 hexane/EtOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 11.20$  min,

 $t_{\text{minor}} = 12.71 \text{ min}$ ; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.26 (s, 3H), 4.95 (d, J = 2.1 Hz, 1H), 5.51 (d, J = 2.1 Hz, 1H), 5.76 (dd, 1H), 6.27 (t, J = 2.2 Hz, 2H), 6.35-6.45 (m, 1H), 6.78-6.92 (m, 1H), 6.96 (d, J = 7.9 Hz, 1H), 6.99-7.08 (m, 3H), 7.08-7.18 (m, 1H), 7.46 (td, J = 7.8, 1.2 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.7, 56.4 (d, J = 7.5 Hz), 65.9, 106.4, 109.5, 109.8, 118.1 (d, J = 16.1 Hz), 119.4, 120.9 (d, J = 4.0 Hz), 122.1, 123.5, 124.0, 124.3 (d, J = 5.4 Hz), 125.8, 131.6, 144.0, 145.7 (d, J = 11.3 Hz), 146.8 (d, J = 258.3 Hz), 171.6; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub>FN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 416.1017; found: 416.1018.



(S)-3-((2S,3R)-5-chloro-2-nitro-2,3-dihydrobenzofuran-3-yl)-1-methyl-3-(1 H-pyrrol-1-yl)indolin-2-one (3d). Light yellow solid; 40.5 mg, 99% yield; >20:1 dr, 95% ee;  $[\alpha]_D^{20} = -136.4$  (*c* 1.73, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 163.1-164.3 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 20.60$  min,  $t_{minor} = 15.51$  min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.25 (s, 3H), 4.88 (d, J = 1.9

Hz, 1H), 5.48 (d, *J* = 1.9 Hz, 1H), 5.83 (d, *J* = 2.3 Hz, 1H), 6.30 (t, *J* = 2.2 Hz, 2H), 6.46-6.58 (m, 1H), 6.95 (t, *J* = 7.9 Hz, 2H), 7.00-7.08 (m, 3H), 7.30 (dd, *J* = 8.6, 2.3 Hz, 1H), 7.42-7.53 (m, 1H);

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 26.7, 56.2, 65.9, 106.4, 109.4, 110.0, 111.3, 119.4, 122.3, 122.5, 123.4, 125.9, 128.6, 130.8, 131.6, 144.0, 157.6, 171.6; HRMS (ESI-TOF) Calcd. for  $C_{21}H_{16}^{35}CIN_3NaO_4$  [M+Na]<sup>+</sup>: 432.0722; found:432.0726; Calcd. for  $C_{21}H_{16}^{37}CIN_3NaO_4$  [M+Na]<sup>+</sup>: 434.0692; found:434.0707.



(S)-3-((2S,3R)-5-bromo-2-nitro-2,3-dihydrobenzofuran-3-yl)-1-methyl-3-(1 H-pyrrol-1-yl)indolin-2-one (3e). Light yellow solid; 43.2 mg, 95% yield; >20:1 dr, 96% ee;  $[\alpha]_D^{20} = -118.1$  (*c* 1.75, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 101.4-102.6 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 20.03$  min,  $t_{minor} = 16.10$  min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.24 (s, 3H), 4.88 (d, J = 2.7

Hz, 1H), 5.48 (d, J = 1.9 Hz, 1H), 5.87-5.98 (m, 1H), 6.30 (t, J = 2.3 Hz, 2H), 6.44-6.57 (m, 1H), 6.89 (d, J = 8.6 Hz, 1H), 6.94-6.99 (m, 1H), 7.00-7.09 (m, 3H), 7.36-7.55 (m, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.7, 56.2, 65.9, 106.3, 109.4, 110.0, 111.8, 115.7, 119.4, 122.3, 122.9, 123.4, 125.9, 128.8, 131.6, 133.6, 144.0, 158.2, 171.5; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub><sup>79</sup>BrN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 476.0216; found: 476.0222; Calcd. for C<sub>21</sub>H<sub>16</sub><sup>81</sup>BrN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 478.0196; found: 478.0195.



(S)-3-((2S,3R)-6-bromo-2-nitro-2,3-dihydrobenzofuran-3-yl)-1-methyl-3-(1 H-pyrrol-1-yl)indolin-2-one (3f). Light yellow solid; 45.0 mg, 99% yield; >20:1 dr, 95% ee;  $[\alpha]_D^{20} = -104.2$  (*c* 2.15, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 108.1-109.4 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (95/5 hexane/PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 22.34$  min,  $t_{minor} = 19.84$  min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.25 (s, 3H), 4.84 (d, J = 2.0

Hz, 1H), 5.46 (d, J = 2.0 Hz, 1H), 5.73-5.83 (m, 1H), 6.26 (t, J = 2.2 Hz, 2H), 6.42-6.56 (m, 1H), 6.95 (d, J = 7.9 Hz, 1H), 7.00-7.08 (m, 4H), 7.18 (d, J = 1.7 Hz, 1H), 7.39-7.58 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.7, 55.8, 65.8, 106.3, 109.4, 109.8, 114.1, 119.4, 119.9, 122.3, 123.4, 124.1, 125.9, 126.6, 126.7, 131.5, 144.0, 159.7, 171.6; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub><sup>79</sup>BrN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 476.0216; found: 476.0221; Calcd. for C<sub>21</sub>H<sub>16</sub><sup>81</sup>BrN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 478.0196; found: 478.0190.



(S)-3-((2S,3R)-7-bromo-2-nitro-2,3-dihydrobenzofuran-3-yl)-1-methyl-3-(1H-pyrrol-1-yl)indolin-2-one (3g). Light yellow solid; 41.3 mg, 91% yield; >20:1 dr, 87% ee;  $[\alpha]_D^{20} = -14.0$  (*c* 1.40, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 208.3-209.7 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 17.72$  min,

 $t_{\text{minor}} = 15.86 \text{ min}$ ; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.26 (s, 3H), 4.98 (d, J = 2.2 Hz, 1H), 5.45 (d, J = 2.0 Hz, 1H), 5.90 (dt, J = 7.5, 1.0 Hz, 1H), 6.26 (t, J = 2.2 Hz, 2H), 6.29-6.36 (m, 1H), 6.80 (t, J = 7.8 Hz, 1H), 6.92-7.06 (m, 4H), 7.39-7.57 (m, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.8, 56.9, 65.9, 102.9, 105.4, 109.5, 109.8, 119.4, 121.9, 122.1, 123.4, 124.6, 124.8, 126.0, 131.7, 133.9, 144.0, 156.5, 171.6; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub><sup>79</sup>BrN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 476.0216; found: 476.0231; Calcd. for C<sub>21</sub>H<sub>16</sub><sup>81</sup>BrN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 478.0196; found: 478.0195.



(S)-3-((2S,3R)-2,5-dinitro-2,3-dihydrobenzofuran-3-yl)-1-methyl-3-(1H-pyr rol-1-yl)indolin-2-one (3h). Light yellow solid; 41.5 mg, 99% yield; >20:1 dr, 90% ee;  $[\alpha]_D{}^{20} = -130.9$  (*c* 1.83, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 212.1-213.4 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 34.71$  min,  $t_{minor} =$ 

27.81 min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.24 (s, 3H), 4.94 (d, J = 2.0 Hz, 1H), 5.67 (d, J = 2.1 Hz, 1H), 6.34 (t, J = 2.2 Hz, 2H), 6.52-6.64 (m, 1H), 6.66-6.71 (m, 1H), 6.98 (d, J = 7.9 Hz, 1H), 7.03-7.17 (m, 4H), 7.42-7.54 (m, 1H), 8.29 (dd, J = 8.9, 2.4 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.8, 55.6, 65.7, 106.5, 109.7, 110.5, 110.6, 119.3, 122.1, 122.3, 122.4, 123.6, 125.5, 127.7, 131.9, 143.9, 144.1, 163.2, 171.2; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub>BrN<sub>4</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>: 443.0962; found: 443.0966.



(S)-1-methyl-3-((2S,3R)-5-methyl-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-(1 H-pyrrol-1-yl)indolin-2-one (3i). Light yellow solid; 38.5 mg, 99% yield; >20:1 dr, 96% ee;  $[\alpha]_D^{20} = -106.5$  (*c* 1.55, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 171.5-172.7 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 17.26$  min,  $t_{minor} = 13.95$  min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  2.15 (s, 3H), 3.24 (s, 3H),

4.86 (d, J = 2.5 Hz, 1H), 5.42 (d, J = 1.8 Hz, 1H), 5.65-5.78 (m, 1H), 6.27 (t, J = 2.3 Hz, 2H), 6.34-6.45 (m, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.91-6.96 (m, 1H), 6.96-7.02 (m, 1H), 7.04 (t, J = 2.3 Hz, 2H), 7.08-7.15 (m, 1H), 7.37-7.51 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  20.7, 26.7, 56.2, 66.1, 106.4, 109.2, 109.5, 109.7, 119.4, 120.3, 122.5, 123.2, 126.1, 126.2, 131.1, 131.3, 133.0, 144.0, 157.1, 171.9; HRMS (ESI-TOF) Calcd. for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 412.1268; found: 412.1270.



(S)-1-methyl-3-((2S,3R)-6-methyl-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-( 1H-pyrrol-1-yl)indolin-2-one (3j). Light yellow solid; 38.6 mg, 99% yield; >20:1 dr, 96% ee;  $[\alpha]_D{}^{20} = -73.1$  (*c* 1.64, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 175.1-176.4 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (95/5 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 24.04$  min,  $t_{minor} = 17.87$  min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  2.36 (s, 3H), 3.24 (s, 3H),

4.81-4.91 (m, 1H), 5.45 (d, J = 1.9 Hz, 1H), 5.86 (d, J = 7.7 Hz, 1H), 6.26 (t, J = 2.2 Hz, 2H), 6.40-6.47 (m, 1H), 6.66-6.74 (m, 1H), 6.82 (d, J = 1.4 Hz, 1H), 6.94 (d, J = 7.9 Hz, 1H), 6.96-7.05 (m, 3H), 7.39-7.48 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  21.6, 26.7, 55.9, 66.1, 106.4, 109.2, 109.5, 110.9, 117.3, 119.4, 122.6, 123.2, 124.3, 125.1, 126.1, 131.3, 141.5, 144.0, 159.3, 171.9; HRMS (ESI-TOF) Calcd. for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 412.1268; found: 412.1263.



(S)-3-((2S,3R)-5-methoxy-2-nitro-2,3-dihydrobenzofuran-3-yl)-1-methyl-3-( 1H-pyrrol-1-yl)indolin-2-one (3k). Light yellow solid; 39.2 mg, 97% yield; >20:1 dr, 93% ee;  $[\alpha]_D{}^{20}$  = -105.9 (*c* 1.56, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 185.3-186.6 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda$  = 254 nm;  $t_{major}$  = 25.48 min,  $t_{minor}$  = 17.49 min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.27 (s, 3H), 3.54 (s, 3H),

4.87 (d, J = 1.8 Hz, 1H), 5.37 (d, J = 1.8 Hz, 1H), 5.46 (d, J = 2.5 Hz, 1H), 6.27 (t, J = 2.2 Hz, 2H), 6.34-6.40 (m, 1H), 6.82-6.93 (m, 2H), 6.93-7.01 (m, 2H), 7.05 (t, J = 2.2 Hz, 2H), 7.40-7.49 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.7, 55.6, 56.5, 65.9, 106.6, 109.3, 109.5, 109.6, 117.3, 119.2, 119.5, 121.1, 122.1, 123.2, 126.3, 131.4, 144.0, 152.9, 155.9, 171.9; HRMS (ESI-TOF) Calcd. for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>NaO<sub>5</sub> [M+Na]<sup>+</sup>: 428.1217; found: 428.1216.



(S)-3-((2S,3R)-5-(tert-butyl)-2-nitro-2,3-dihydrobenzofuran-3-yl)-1-methyl-3-(1H-pyrrol-1-yl)indolin-2-one (3l). Light yellow solid; 42.6 mg, 99% yield; >20:1 dr, 95% ee;  $[\alpha]_D^{20} = -85.1$  (*c* 1.65, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 198.0-199.1 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/<sup>j</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 11.82$  min,  $t_{minor} = 9.18$  min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  1.13 (s, 9H), 3.21 (s, 3H), 4.87 (d, J = 2.5 Hz, 1H), 5.50 (d, J = 1.8 Hz, 1H), 5.94 (d, J = 2.1 Hz, 1H), 6.28 (t, J = 2.2 Hz, 2H), 6.39 (d, J = 7.5 Hz, 1H), 6.85-6.96 (m, 2H), 6.97-7.09 (m, 3H), 7.30-7.36 (m, 1H), 7.39-7.47 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.6, 31.3, 34.4, 56.2, 66.2, 106.6, 109.2, 109.3, 109.6, 119.4, 119.9, 122.7, 122.9, 123.3, 126.0, 127.4, 131.2, 143.9, 146.6, 156.8, 171.9; HRMS (ESI-TOF) Calcd. for C<sub>25</sub>H<sub>25</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 454.1737; found: 454.1739.



(S)-3-((2S,3R)-5,7-dibromo-2-nitro-2,3-dihydrobenzofuran-3-yl)-1-meth yl-3-(1H-pyrrol-1-yl)indolin-2-one (3m). Light yellow solid; 49.2 mg, 92% yield; >20:1 dr, 91% ee;  $[\alpha]_D{}^{20}$  = -79.2 (*c* 1.81, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 142.3-143.5 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/<sup>*i*</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda$  = 254 nm; *t*<sub>major</sub> = 19.58 min, *t*<sub>minor</sub> = 15.90 min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.27 (s, 3H), 4.94 (d, *J* =

2.1 Hz, 1H), 5.44 (d, J = 2.1 Hz, 1H), 5.79-5.90 (m, 1H), 6.30 (t, J = 2.2 Hz, 2H), 6.38-6.52 (m, 1H), 6.99 (d, J = 7.9 Hz, 1H), 7.01-7.10 (m, 3H), 7.43-7.55 (m, 1H), 7.64 (d, J = 1.9 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.8, 57.2, 65.7, 103.6, 105.5, 109.6, 110.1, 116.1, 119.3, 121.7, 123.5, 123.8, 125.9, 127.9, 131.9, 136.0, 144.0, 155.9, 171.4; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>15</sub><sup>79</sup>Br<sub>2</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 553.9314; found: 553.9322; Calcd. for C<sub>21</sub>H<sub>15</sub><sup>81</sup>Br<sub>2</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 555.9301; found: 557.929; Calcd. for C<sub>21</sub>H<sub>15</sub><sup>79</sup>Br<sup>81</sup>BrN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 555.9301; found: 555.9317.



(S)-1-ethyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-(1H-pyrrol-1yl)indolin-2-one (3n). Light yellow solid; 35.8 mg, 92% yield; 17:1 dr, 89% ee;  $[\alpha]_D^{20} = -4.7$  (*c* 1.83, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 157.1-158.4 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (95/5 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 33.69$  min,  $t_{minor} = 28.42$  min); <sup>1</sup>H NMR (300

MHz, CDCl<sub>3</sub>)  $\delta$  1.08 (t, J = 7.1 Hz, 3H), 3.47-3.67 (m, 1H), 3.79-3.98 (m, 1H), 4.89 (d, J = 1.8 Hz, 1H), 5.67 (d, J = 1.8 Hz, 1H), 5.93 (d, J = 7.6 Hz, 1H), 6.29 (t, J = 2.2 Hz, 2H), 6.61 (d, J = 7.6 Hz, 1H), 6.80-6.89 (m, 1H), 6.92 (d, J = 7.9 Hz, 1H), 6.98-7.10 (m, 4H), 7.25-7.35 (m, 1H), 7.39-7.47 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  12.2, 35.1, 56.1, 66.1, 106.3, 109.3, 109.7, 110.0, 110.4, 120.3, 123.1, 123.2, 123.6, 125.4, 125.7, 130.7, 131.1, 142.8, 159.0, 171.2; HRMS (ESI-TOF) Calcd. for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 412.1268; found: 412.1263.



(S)-1-benzyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-(1H-pyrrol-1-yl)indolin-2-one (30). Light yellow solid; 40.1 mg, 89% yield; 13:1 dr, 91% ee;  $[\alpha]_D^{20} = +37.9$  (*c* 1.71, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 170.2-171.3 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (95/5 hexane/EtOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 12.55$  min,  $t_{minor} =$ 

15.85 min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.58 (d, J = 15.4 Hz, 1H), 4.98 (d, J = 1.8 Hz, 1H), 5.19 (d, J = 15.4 Hz, 1H), 5.62 (d, J = 1.8 Hz, 1H), 6.01 (d, J = 7.5 Hz, 1H), 6.32 (q, J = 2.5 Hz, 2H), 6.54 (d, J = 7.5 Hz, 1H), 6.80-6.91 (m, 2H), 6.94-7.05 (m, 2H), 7.10 (t, J = 2.3 Hz, 2H), 7.16-7.22 (m, 2H), 7.27-7.35 (m, 5H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  44.4, 56.1, 66.1, 106.1, 109.8, 110.3, 119.4, 119.6, 120.3, 123.3, 123.4, 125.6, 125.7, 127.7, 128.0, 128.8, 129.0, 130.8, 131.1, 134.8, 142.9, 159.1, 171.9; HRMS (ESI-TOF) Calcd. for C<sub>27</sub>H<sub>21</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 474.1424; found: 474.1426.



(S)-1-allyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-(1H-pyrrol-1-y l)indolin-2-one (3p). Light yellow solid; 38.8 mg, 97% yield; 10:1 dr, 86% ee;  $[\alpha]_D{}^{20} = +12.3$  (*c* 1.95, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 161.3-162.4 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (95/5 hexane/<sup>*i*</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 29.01$  min,  $t_{minor} = 26.33$  min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.13-4.25 (m, 1H), 4.38-4.50 (m, 1H), 4.87-4.96 (m, 1H),

5.08-5.24 (m, 2H), 5.53-5.72 (m, 2H), 5.97 (d, J = 7.6 Hz, 1H), 6.29 (q, J = 2.1 Hz, 2H), 6.58 (d, J = 7.5 Hz, 1H), 6.81-6.95 (m, 2H), 6.97-7.11 (m, 4H), 7.24-7.36 (m, 1H), 7.36-7.48 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  42.7, 56.0, 66.1, 106.3, 109.8, 110.1, 110.4, 118.7, 119.4, 119.6, 120.3, 123.3, 124.2, 125.5, 125.6, 130.3, 130.8, 131.1, 142.9, 159.1, 171.4; HRMS (ESI-TOF) Calcd. for C<sub>23</sub>H<sub>19</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 424.1268; found: 424.1264.



(S)-5-fluoro-1-methyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-( 1H-pyrrol-1-yl)indolin-2-one (3q). Light yellow solid; 38.5 mg, 98% yield; >20:1 dr, 93% ee;  $[\alpha]_D^{20} = -45.4$  (*c* 1.56, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 169.3-170.4 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 19.25$  min,

 $t_{\text{minor}} = 26.56 \text{ min}$ ; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.22 (s, 3H), 4.87-4.97 (m, 1H), 5.49 (d, J = 1.8 Hz, 1H), 6.01 (d, J = 7.5 Hz, 1H), 6.04-6.15 (m, 1H), 6.29 (t, J = 2.2 Hz, 2H), 6.84-6.95 (m, 2H), 6.98-7.07 (m, 3H), 7.11-7.22 (m, 1H), 7.30-7.41 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.8, 55.8, 66.3, 105.9, 109.9, 110.0, 110.5, 114.2 (d, J = 25.6 Hz), 118.0 (d, J = 23.4 Hz), 119.3, 119.9, 123.6, 123.9 (d, J = 7.9 Hz), 125.5, 131.1, 139.9, 158.8 (d, J = 242.4 Hz), 159.0, 171.6; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub>FN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 416.1017; found: 416.1028.



(S)-5-chloro-1-methyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-(1H-pyrrol-1-yl)indolin-2-one (3r). Light yellow solid; 40.5 mg, 99% yield; >20:1 dr, 92% ee;  $[\alpha]_D^{20} = -36.2$  (*c* 1.65, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 194.7-150.8 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 17.07$  min,

 $t_{\text{minor}} = 23.58 \text{ min}$ ; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.20 (s, 3H), 4.91 (d, J = 2.3 Hz, 1H), 5.51 (d, J = 1.8 Hz, 1H), 5.96-6.06 (m, 1H), 6.24-6.38 (m, 3H), 6.86 (d, J = 8.4 Hz, 1H), 6.88-6.95 (m, 1H), 7.00 (t, J = 2.3 Hz, 2H), 7.04 (d, J = 8.1 Hz, 1H), 7.32-7.39 (m, 1H), 7.39-7.45 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.8, 55.9, 77.4, 105.9, 110.0, 110.2, 110.5, 119.3, 119.9, 123.6, 124.3, 125.5, 126.3, 128.8, 131.1, 131.3, 142.4, 159.0, 171.4; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub><sup>35</sup>ClN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 432.0722; found:432.0729; Calcd. for C<sub>21</sub>H<sub>16</sub><sup>37</sup>ClN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 434.0692; found:434.0713.



(S)-6-chloro-1-methyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3 -(1H-pyrrol-1-yl)indolin-2-one (3s). Light yellow solid; 40.2 mg, 98% yield; >20:1 dr, 95% ee;  $[\alpha]_D^{20} = -76.3$  (*c* 1.64, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 157.3-158.9 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda =$ 

254 nm;  $t_{\text{major}} = 15.34 \text{ min}$ ,  $t_{\text{minor}} = 13.44 \text{ min}$ ); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.22 (s, 3H), 4.90 (d, J = 2.5 Hz, 1H), 5.45 (d, J = 1.8 Hz, 1H), 5.93-6.07 (m, 1H), 6.24 (d, J = 8.7 Hz, 1H), 6.26-6.30 (m, 2H), 6.86-6.94 (m, 1H), 6.94-7.00 (m, 4H), 7.01 (d, J = 8.1 Hz, 1H), 7.30-7.39 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.8, 55.9, 65.8, 105.9, 109.9, 110.1, 110.5, 119.3, 120.1, 120.7, 123.2, 123.6, 125.6, 127.0, 131.0, 137.5, 145.2, 159.0, 171.8; HRMS (ESI-TOF) Calcd. for

 $C_{21}H_{16}{}^{35}ClN_3NaO_4 [M+Na]^+: 432.0722; found: 432.0724; Calcd. for <math>C_{21}H_{16}{}^{37}ClN_3NaO_4 [M+Na]^+: 434.0692; found: 434.0708.$ 



(S)-7-chloro-1-methyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-(1 H-pyrrol-1-yl)indolin-2-one (3t). Light yellow solid; 39.8 mg, 97% yield; >20:1 dr, 90% ee;  $[\alpha]_D^{20} = -33.3$  (*c* 1.87, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 87.2-88.3 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 14.45$  min,  $t_{minor} =$ 

11.73 min); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.56 (s, 3H), 4.92 (d, *J* = 2.3 Hz, 1H), 5.60 (d, *J* = 1.8 Hz, 1H), 5.99 (d, *J* = 7.6 Hz, 1H), 6.28 (t, *J* = 2.2 Hz, 2H), 6.33 (d, *J* = 7.6 Hz, 1H), 6.86-6.94 (m, 2H), 6.97-7.04 (m, 3H), 7.30-7.40 (m, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  30.2, 55.9, 65.7, 106.0, 110.0, 110.5, 116.7, 119.3, 120.0, 123.5, 123.9, 124.3, 125.5, 125.6, 131.0, 133.6, 139.9, 159.0, 172.1; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub><sup>35</sup>ClN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 432.0722; found:432.0738; Calcd. for C<sub>21</sub>H<sub>16</sub><sup>37</sup>ClN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 434.0692; found:434.0722.



(S)-5-bromo-1-methyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-(1H-pyrrol-1-yl)indolin-2-one (3u). Light yellow solid; 43.1 mg, 95% yield; >20:1 dr, 92% ee;  $[\alpha]_D^{20} = -37.3$  (*c* 1.63, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 165.3-166.5 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 17.91$  min,

 $t_{\text{minor}} = 24.91 \text{ min}$ ; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.19 (s, 3H), 4.91 (d, J = 1.7 Hz, 1H), 5.52 (d, J = 1.7 Hz, 1H), 5.96-6.06 (m, 1H), 6.30 (t, J = 2.2 Hz, 2H), 6.43 (d, J = 2.0 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 6.88-6.95 (m, 1H), 7.00 (t, J = 2.2 Hz, 2H), 7.05 (d, J = 8.2 Hz, 1H), 7.33-7.41 (m, 1H), 7.55-7.58 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  26.8, 55.9, 66.3, 105.9, 110.0, 110.5, 110.6, 115.9, 119.3, 119.9, 123.6, 124.6, 125.5, 129.0, 131.1, 134.2, 142.9, 159.0, 171.3; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>16</sub><sup>79</sup>BrN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 476.0216; found: 476.0213; Calcd. for C<sub>21</sub>H<sub>16</sub><sup>81</sup>BrN<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 478.0196; found: 478.0195.



(S)-1,5-dimethyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-3-(1Hpyrrol-1-yl)indolin-2-one (3v). Light yellow solid; 38.1 mg, 98% yield; >20:1 dr, 95% ee;  $[\alpha]_D^{20} = -41.2$  (*c* 1.88, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 96.7-97.9 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{maior} = 24.18$  min,

 $t_{\text{minor}} = 32.61 \text{ min}$ ; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  2.19 (s, 3H), 3.19 (s, 3H), 4.90 (d, J = 2.3 Hz, 1H), 5.50 (d, J = 1.8 Hz, 1H), 5.99 (d, J = 7.6 Hz, 1H), 6.14 (s, 1H), 6.27 (t, J = 2.2 Hz, 2H), 6.82 (d, J = 8.0 Hz, 1H), 6.86-6.94 (m, 1H), 6.97-7.07 (m, 3H), 7.19-7.25 (m, 1H), 7.30-7.37 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  21.0, 26.6, 56.0, 66.3, 106.1, 108.9, 109.5, 110.1, 119.4, 120.5, 122.5, 123.3, 125.6, 126.6, 130.7, 131.5, 132.9, 141.4, 159.1, 171.7; HRMS (ESI-TOF) Calcd. for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>NaO<sub>4</sub> [M+Na]<sup>+</sup>: 412.1268; found: 412.1263.

#### 5. General experimental procedures for asymmetric synthesis of compounds 5

To a solution of catalyst **D** (7.1 mg, 0.01 mmol, 10 mol %) and 2-nitrobenzofuran **1a** (0.12 mmol) in xylene (1.0 mL) was added 3-monosubstituted oxindoles **4** (0.1 mmol) at -20 °C or rt. Then the mixture was stirred continuously for specific time at -20 °C or rt. After completion, the reaction mixture was directly purified by flash chromatography on silica gel (petroleum ether/ethyl acetate =  $3:1 \sim 6:1$ ) to give the corresponding products **5**.



methyl (R)-3-methyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-2oxoindoline-1-carboxylate (5a). Light yellow solid; 36.4 mg, 99% yield; 13:1 dr, 95% ee;  $[\alpha]_D^{20} = +17.2$  (*c* 1.00, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 165.0-166.1 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (70/30 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{maior} = 8.27$  min,  $t_{minor} =$ 

9.24 min); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.83 (s, 3H), 3.91 (s, 3H), 4.10 (d, *J*= 1.6 Hz), 6.11 (d, *J* = 7.6 Hz, 1H), 6.47 (d, *J* = 1.9 Hz, 1H), 6.68-6.82 (m, 1H), 7.03 (d, *J* = 8.1 Hz, 1H), 7.11-7.16 (m, 1H), 7.21-7.33 (m, 2H), 7.41-7.48 (m, 1H), 7.91 (d, *J* = 8.1 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  22.6, 50.1, 54.1, 57.3, 107.0, 111.0, 115.6, 121.3, 122.8, 122.9, 124.8, 125.4, 129.5, 129.6, 130.6, 139.2, 150.8, 158.4, 176.0; HRMS (ESI-TOF) Calcd. for C<sub>19</sub>H<sub>16</sub>N<sub>2</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>: 391.0901; found: 391.0900.



ethyl (R)-3-ethyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-2-oxoind oline-1-carboxylate (5b). Light yellow solid; 37.2 mg, 94% yield; 10:1 dr, 94% ee;  $[\alpha]_D^{20} = +22.6$  (*c* 1.00, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 116.9-118.0 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (90/10 hexane/<sup>*i*</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{maior} = 14.74$  min,  $t_{minor} =$ 

16.08 min); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  (major diastereomers) 0.76 (t, J = 7.4 Hz, 3H), 1.36 (t, J = 7.1 Hz, 3H), 2.12-2.28 (m, 1H), 2.43-2.59 (m, 1H), 4.11 (d, J = 2.4 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 6.09 (d, J = 7.6 Hz, 1H), 6.50 (d, J = 1.9 Hz, 1H), 6.70-6.78 (m, 1H), 7.02 (d, J = 8.1 Hz, 1H), 7.06-7.11 (m, 1H), 7.21-7.26 (m, 1H), 7.27-7.34 (m, 1H), 7.38-7.52 (m, 1H), 7.81-7.93 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  (major diastereomers) 8.5, 14.1, 29.3, 55.5, 56.9, 63.6, 107.0, 110.9, 115.4, 121.3, 122.7, 123.0, 124.9, 125.2, 127.5, 129.6, 130.4, 140.4, 150.1, 158.4, 175.5; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>20</sub>N<sub>2</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>: 419.1214; found: 419.1200.



ethyl (R)-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-2-oxo-3-propy lindoline-1-carboxylate (5c). Light yellow solid; 39.0 mg, 95% yield; >20:1 dr, 94% ee;  $[\alpha]_D^{20} = +71.7$  (*c* 1.00, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 202.0-203.0 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{maior} = 10.68$  min,  $t_{minor} =$ 

13.56 min); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.91 (t, *J* = 7.1 Hz, 3H), 0.96-1.05 (m, 1H), 1.09-1.22 (m, 1H), 1.31-1.41 (m, 3H), 2.09-2.21 (m, 1H), 2.33-2.49 (m, 1H), 4.10 (d, *J* = 1.8 Hz, 1H), 4.36 (q, *J* = 7.1 Hz, 2H), 6.06 (d, *J* = 7.6 Hz, 1H), 6.52 (d, *J* = 1.9 Hz, 1H), 6.67-6.79 (m, 1H), 7.02 (d, *J* = 8.1 Hz, 1H), 7.07-7.14 (m, 1H), 7.19-7.26 (m, 1H), 7.27-7.33 (m, 1H), 7.38-7.48 (m, 1H), 7.86 (d, *J* = 8.2 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  14.0, 14.1, 17.6, 38.2, 54.9, 57.0, 63.6, 107.0, 110.9, 115.4, 121.2, 122.6, 123.0, 124.9, 125.2, 127.9, 129.5, 130.4, 140.2, 150.1, 158.4, 175.6; HRMS (ESI-TOF) Calcd. for C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>: 433.1370; found: 433.1377.



methyl (R)-3-(2-ethoxy-2-oxoethyl)-3-((2S,3R)-2-nitro-2,3-dihydrobenzo furan-3-yl)-2-oxoindoline-1-carboxylate (5d). Light yellow solid; 30.8 mg, 70% yield; 16:1 dr, 94% ee;  $[\alpha]_D^{20} = +36.1$  (*c* 1.00, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 171.2-172.1 °C. The ee was determined by HPLC analysis using a Chiralpak IC-H column (90/10 hexane/<sup>i</sup>PrOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} =$ 

15.83 min,  $t_{minor} = 10.70$  min); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.05 (t, J = 7.1 Hz, 3H), 3.31 (d, J = 16.5 Hz, 1H), 3.56 (d, J = 16.5 Hz, 1H), 3.91 (s, 3H), 3.92-3.96 (m, 1H), 3.96-4.02 (m, 1H), 4.12 (d, J = 2.3 Hz, 1H), 6.02 (d, J = 7.6 Hz, 1H), 6.45 (d, J = 1.9 Hz, 1H), 6.69-6.82 (m, 1H), 7.03 (d, J = 8.1 Hz, 1H), 7.13 (d, J = 7.5 Hz, 1H), 7.23-7.30 (m, 2H), 7.42-7.49 (m, 1H), 7.88-7.97 (m, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 13.7, 40.4, 51.4, 54.1, 56.7, 61.4, 106.3, 111.1, 115.6, 120.2, 122.7, 122.9, 125.0, 125.2, 126.9, 130.0, 130.8, 140.7, 150.8, 158.5, 168.5, 174.8; HRMS (ESI-TOF) Calcd. for  $C_{22}H_{20}N_2NaO_8$  [M+Na]<sup>+</sup>: 463.1112; found: 463.1109.



methyl (R)-3-allyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)-2-oxo indoline-1-carboxylate (5e). Light yellow solid; 32.3 mg, 84% yield; 3:1 dr, 94% ee;  $[\alpha]_D^{20} = +8.4$  (*c* 1.00, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 176.0-177.0 °C. The ee was determined by HPLC analysis using a Chiralpak AD-H column (90/10 hexane/<sup>i</sup>PrOH; flow

<sup>CO<sub>2</sub>Me rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 23.13$  min,  $t_{minor} = 63.01$  min); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (major diastereomers) 2.97 (dd, J = 13.6, 6.6 Hz, 1H), 3.12 (dd, J = 13.5, 7.9 Hz, 1H), 3.91 (s, 3H), 5.07-4.97 (m, 1H), 5.18-5.10 (m, 1H), 5.51-5.27 (m, 1H), 6.12 (d, J = 7.5 Hz, 1H), 6.54 (d, J = 1.5 Hz, 1H), 6.75 (t, J = 7.5 Hz, 1H), 7.03 (d, J = 8.1 Hz, 1H), 7.16-7.10 (m, 1H), 7.25-7.20 (m, 1H), 7.34-7.25 (m, 2H), 7.49-7.39 (m, 1H), 7.89 (d, J = 8.2 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ (major diastereomers) 40.4, 54.0, 54.7, 56.3, 106.9, 111.0, 115.5, 121.1, 121.2, 122.8, 123.4, 125.0, 125.2, 127.2, 129.7, 129.8, 130.6, 140.0, 150.7, 158.5, 174.9; HRMS (ESI-TOF) Calcd. for C<sub>21</sub>H<sub>18</sub>N<sub>2</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>: 417.1057; found: 417.1053.</sup>



(**R**)-1-acetyl-3-benzyl-3-((2S,3R)-2-nitro-2,3-dihydrobenzofuran-3-yl)indoli n-2-one (5f). Light yellow solid; 34.2 mg, 80% yield; 10:1 dr, 71% ee;  $[\alpha]_D^{20}$  = +41.4 (*c* 1.00, CH<sub>2</sub>Cl<sub>2</sub>); m.p. 186.1-187.0 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (85/15 hexane/EtOH; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 9.96$  min,  $t_{minor} = 14.07$  min); <sup>1</sup>H NMR (400 MHz,

CDCl<sub>3</sub>)  $\delta$  (major diastereomers) 2.34 (s, 3H), 3.45 (d, *J* = 13.0 Hz, 1H), 3.75 (d, *J* = 13.0 Hz, 1H), 4.35 (d, *J* = 1.9 Hz, 1H), 6.33 (d, *J* = 7.6 Hz, 1H), 6.52 (d, *J* = 1.9 Hz, 1H), 6.77-6.89 (m, 3H), 7.02-7.11 (m, 4H), 7.12-7.18 (m, 1H), 7.28-7.38 (m, 3H), 7.87-8.00 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  (major diastereomers) 26.1, 42.4, 56.5, 56.6, 107.1, 110.9, 116.6, 121.3, 123.0, 123.4, 125.3, 125.4, 126.9, 127.4, 128.1, 129.6, 129.7, 130.7, 133.4, 140.7, 158.6, 169.9, 177.4; HRMS (ESI-TOF) Calcd. for C<sub>25</sub>H<sub>20</sub>N<sub>2</sub>NaO<sub>5</sub> [M+Na]<sup>+</sup>: 451.1264; found: 451.1262.



ethyl 3-(-2-nitro-2,3-dihydrobenzofuran-3-yl)-2-oxo-3-phenylindoline-1carboxylate (5g). Light yellow solid; 22.2 mg, 50% yield; >20:1 dr, 0 ee; m.p. 224.0-225.1 °C. The ee was determined by HPLC analysis using a Chiralpak IA-H column (90/10 hexane/<sup>*i*</sup>PrOH;; flow rate: 1.0 mL/min;  $\lambda = 254$  nm;  $t_{major} = 17.42$  min,  $t_{minor} = 18.81$  min); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.43 (t, J = 7.1

Hz, 3H), 4.45 (q, J = 7.1 Hz, 2H), 5.00 (d, J = 1.8 Hz, 1H), 5.78 (d, J = 1.7 Hz, 1H), 6.02 (d, J = 7.6 Hz, 1H), 6.56 (d, J = 7.6 Hz, 1H), 6.71-6.87 (m, 1H), 7.03 (d, J = 8.1 Hz, 1H), 7.09-7.21 (m, 1H), 7.24-7.32 (m, 1H), 7.41-7.49 (m, 4H), 7.52-7.60 (m, 2H), 8.00 (d, J = 8.2 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 14.2, 56.4, 58.7, 63.8, 107.8, 110.8, 115.7, 121.8, 122.8, 125.0, 125.2, 125.3, 126.3, 127.8, 128.7, 129.2, 129.9, 130.7, 135.9, 139.5, 150.4, 159.1, 173.8; HRMS (ESI-TOF) Calcd. for C<sub>25</sub>H<sub>20</sub>N<sub>2</sub>NaO<sub>6</sub> [M+Na]<sup>+</sup>: 467.1214; found: 467.1217.

### 6. Scale-up experiment

To a solution of catalyst **E** (106.5 mg, 5 mol %) and 2-nitrobenzofuran **1a** (0.587 g, 3.6 mmol) in xylene (30.0 mL) was added 3-pyrrolyl-oxindole **2a** (0.636 g, 3.0 mmol) at -20 °C. Then the mixture was stirred continuously for 84 h at -20 °C. After completion, the reaction mixture was directly purified by flash chromatography on silica gel (petroleum ether/ethyl acetate = 3:1) to give the corresponding product **3a** in 99% yield (1.115 g).

7. X-Ray crystal data for compounds 3c

Single crystals of compound **3d** were prepared from the mixture solvent of EtOH and CH<sub>2</sub>Cl<sub>2</sub>. A suitable crystal was selected for structure determination on a Xcalibur, Eos, Gemini diffractometer. The crystal was kept at 293(2) K during data collection. Using Olex2, the structure was solved with the ShelXS structure solution program using Direct Methods and refined with the ShelXLrefinement package using Least Squares minimisation.



ORTEP of **3d** (at 50% level)

Crystal data and structure refinement for 3d (1943699) Identification code 3d Empirical formula  $C_{21}H_{16}ClN_3O_4$ Formula weight 409.82 Temperature/K 293(2) Crystal system monoclinic Space group P21 a/Å 9.3140(4) b/Å 21.8053(13) c/Å 9.5831(5)  $\alpha/^{\circ}$ 90 β/° 94.306(4) γ/° 90 Volume/Å<sup>3</sup> 1940.77(17) Ζ 4  $\rho_{calc}g/cm^3$ 1.403  $\mu/\text{mm}^{-1}$ 2.035 F(000) 848.0 Crystal size/mm<sup>3</sup>  $0.15 \times 0.13 \times 0.1$ Radiation CuK $\alpha$  ( $\lambda = 1.54184$ ) 20 range for data collection/° 8.11 to 134.14 Index ranges  $-11 \le h \le 11, -26 \le k \le 23, -11 \le l \le 10$ Reflections collected 18941  $6342 \ [R_{int} = 0.0369, R_{sigma} = 0.0402]$ Independent reflections Data/restraints/parameters 6342/1/525 Goodness-of-fit on F<sup>2</sup> 1.032 Final R indexes  $[I \ge 2\sigma(I)]$  $R_1 = 0.0448$ ,  $wR_2 = 0.1130$ Final R indexes [all data]  $R_1 = 0.0508, wR_2 = 0.1204$ Largest diff. peak/hole / e Å<sup>-3</sup> 0.15/-0.18

-0.011(10)

Flack parameter

8. Proposed activation mode of the chiral catalyst D to the reaction between 3-monosubstituted oxindoles and 2-nitrobenzofurans.



In light of the multiple hydrogen-bonding bifunctional thiourea catalytic model<sup>[ref,1]</sup> and other relevant reports,<sup>[ref,2]</sup> we have proposed a possible activation mode to account for the stereochemistry of the Michael addition process between 3-monosubstituted oxindole and 2-nitrobenzofuran. The substrate 2-nitrobenzofuran is activated and oriented by the multiple hydrogen bonds of thiourea and amide moieties of the catalyst **D**, while the tertiary nitrogen of the cinchonidine would provide suitable basicity to enhance the nucleophilicity of the 3-monosubstituted oxindole. Under this dual-activation model, the C3-position of 3-monosubstituted oxindole from *Re*-face attacks the *Si*-face of C3-position of 2-nitrobenzofuran, which undergoes the Michael addition to provide the 3,3'-disubstituted oxindole product with (*C2S, C10S, C11R*) configuration.

[*ref.1*] For selected reviews of bifunctional thiourea catalysis, see: (a) Y. Takemoto, *Org. Biomol. Chem.* 2005, 3, 4299. (b) A. G. Doyle and E. N. Jacobsen, *Chem. Rev.* 2007, 107, 5713. (c) X. Yu and W. Wang, *Chem. Asian J.* 2008, 3, 516. (d) Z. Zhang and P. R. chreiner, *Chem. Soc. Rev.* 2009, 38, 1187. (e) X. Fang and C.-J. Wang, *Chem. Commun.* 2015, 51, 1185. For selected examples, see: (f) T. Okino, Y. Hoashi and Y. Takemoto, *J. Am. Chem. Soc.* 2003, 125, 12672. (g) J. Ye, D. J. Dixon and P. S. Hynes, *Chem. Commun.* 2005, 4481. (h) J. P. Malerich, K. Hagihara and V. H. Rawal, *J. Am. Chem. Soc.* 2008, 130, 14416. (i) Q. Zhu, and Y. Lu, *Angew. Chem., Int. Ed.* 2010, 49, 7753. (j) X. Dou, W. Yao, B. Zhou and Y. Lu, *Chem. Commun.* 2013, 49, 9224. (k) D.-F. Yue, J.-Q. Zhao, Y.-Z. Chen, X.-M. Zhang, X.-Y. Xu and W.-C. Yuan, *Adv. Synth. Catal.* 2018, 360, 1420.

[*ref.2*] For selected examples, see: (a) Q. Cheng, H.-J. Zhang, W.-J. Yue and S.-L. You, *Chem.*, 2017, **3**, 428; (b) J.-Q. Zhao, X.-J. Zhou, Y. Zhou, X.-Y. Xu, X.-M. Zhang and W.-C. Yuan, *Org. Lett.* 2018, **20**, 909; (c) L. Liang H.-Y. Niu, D.-C. Wang, X.-H. Yang, G.-R. Qu and H.-M. Guo, *Chem. Commun.*, 2019, **55**, 553; (d) J.-Q. Zhao, Y. Yang, X.-J. Zhou, Y. You, Z.-H. Wang, M.-Q. Zhou, X.-M. Zhang, X.-Y. Xu and W.-C. Yuan, *Org. Lett.*, 2019, **21**, 660; (e) X.-J. Zhou, J.-Q. Zhao, X.-M. Chen, J.-R. Zhuo, Y.-P. Zhang, Y.-Z. Chen, X.-M. Zhang, X.-Y. Xu and W.-C. Yuan, *J. Org. Chem.*, 2019, **84**, 4381; (f) X.-H. Yang, J.-P. Li, D.-C.Wang, M.-S. Xie, G.-R. Qu and H.-M. Guo, *Chem. Commun.*, 2019, **55**, 9144.

### 9. General experimental procedures for in vitro cytotoxicity assay

Three human cancer cell lines, human leukemia cells K562, human lung cancer cells A549 andhuman prostate cancer cells PC-3 were purchased from Chinese Academy of Sciences,

Kunming Cell Bank and Chinese Academy of Sciences, Shanghai Cell Bank respectively. All the cells werecultured in RPMI-1640 medium (GIBICO, USA), supplemented with 10% fetal bovine serum (Hyclone, USA) and Penicillin-Streptomycin (respectively 100 U/mL) in 5% CO<sub>2</sub> at 37 °C. The performed according cytotoxicity assay was to the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) method in 96-well microplates. Briefly, 5000 cells were seeded into each well of 96-well cell culture plates and allowed to grow for 24 h before the drug is added. Unless K562 tumor cell line was exposed to compounds (3a, 3c, 3e, 3h, 3j, 3k, 3g, 3m, 3r, 3s, 3u and 3v) at the concentrations of 1, 2, 4, 8 and 20  $\mu$ mol·L<sup>-1</sup>, each A549 or PC-3 tumor cell line was exposed to the test compounds (3a, 3c, 3e, 3h, 3j, 3k, 3g, 3m, **3r**, **3s**, **3u** and **3v**) at the concentrations of 5, 10, 20, 40 and 80  $\mu$ mol<sup>·</sup>L<sup>-1</sup> in triplicates for 48 h, comparable to cisplatin (Aladdin, China). Then the MTT reagent was added to reaction with the cancer cells for 4 hours. At least, measure the OD value at 490 wavelengths. The average 50% inhibitory concentration (IC<sub>50</sub>) of all the compounds is calculated by IBM SPSS Statistics (version 19). Each concentration was analyzed in triplicate at least, and the whole experiment was repeated three times.

1		$IC_{50} (uM)^{a}$	
compound -	K562	A549	PC-3
3a	50.39	29.75	32.55
3c	13.04	10.14	13.44
3e	35.93	52.45	19.50
3h	16.99	33.02	12.80
3j	10.36	9.04	20.93
3k	14.78	12.04	17.83
3g	29.58	23.57	25.50
3m	18.84	34.67	17.96
3r	27.93	29.25	8.52
3s	20.58	33.06	27.71
3u	20.28	29.61	29.49
3v	32.59	32.33	9.33
cisplatin <sup>b</sup>	21.77	17.40	20.33

Table 1. Cell Inhibitory Ass	ay of target products in	K562, A549	, and PC-3 Cells
------------------------------	--------------------------	------------	------------------

 ${}^{a}$ IC<sub>50</sub> is the concentration of a compound that affords a 50% reduction in cell growth (after 48 h of incubation), expressed as the mean of triplicate experiments.  ${}^{b}$ Commercially available broad-spectrum anticancer drug cisplatin as a positive control.

# 10. <sup>1</sup>H, <sup>13</sup>C NMR, and HPLC spectra for compounds 3 and 5

ſ 11 `Ń CH₃ 0.97 1.05 2.12 2.12 2.07 2.07 2.05 A 3.00H <u>1-00</u> 1.00<u>1</u> 5.0 4.5 f1 (ppm) 5.5 9.0 8.0 6.0 3.5 2.5 -0.5 9.5 8.5 7.5 7.0 6.5 4.0 3.0 2.0 1.5 1.0 0.5 0.0 -171.825 -159.081 -143.964  $\begin{array}{c} & 131.356 \\ \hline & 130.771 \\ 130.771 \\ 125.632 \\ 125.632 \\ 122.568 \\ 122.568 \\ 122.558 \\ 122.558 \\ 122.558 \\ 122.558 \\ 122.558 \\ 102.477 \\ 100.638 \\ 100.638 \\ 100.658 \\ 100.259 \\ 10$ +77.412 +76.565 -66.122 -56.038-26,669 H ≟ ⊂O NO₂ ĊН<sub>3</sub>

<sup>1</sup>H and <sup>13</sup>C NMR of **3a** 

100 90 fl (ppm) 70

60

50

40

80

0

20

30

10

130 120

140

110

190

180

170

160

150







A (254nm) Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	14.147	10187	2.40	344081	1.79
2	17.553	11310	2.66	527515	2.75
3	21.340	403767	94.95	18334981	95.46
Totals					
		425264	100.00	19206577	100.00

<sup>1</sup>H and <sup>13</sup>C NMR of **3b** 









Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	15.607	15245	3.41	573855	2.46
2	26.610	431264	96.59	22713853	97.54
Totals					
		446509	100.00	23287708	100.00







A (254nm) Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	10.993	360180	52.66	8178156	50.45
2	12.587	323732	47.34	8032784	49.55
Totals					
		683912	100.00	16210940	100.00



Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	11.197	590034	94.31	12559009	93.76
2	12.710	35579	5.69	836294	6.24
Totals					
		625613	100.00	13395303	100.00

<sup>1</sup>H and <sup>13</sup>C NMR of **3d** 









18.7	Recention fille	rieight	fieight i creent	Alca	Area refeeline
1	15.507	15690	2.69	647036	2.42
2	20.603	566719	97.31	26106923	97.58
Totals					
		582409	100.00	26753959	100.00









<sup>1</sup>H and <sup>13</sup>C NMR of **3f** 









Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	19.840	16221	2.63	769633	2.55
2	22.340	600206	97.37	29364555	97.45
I otals					
		616427	100.00	30134188	100.00



S25

















100.00

32385854

100.00

319745



S29





100.00

23906171

100.00

643729









A (254nm) Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	17.790	294075	52.93	13263310	49.96
2	24.123	261543	47.07	13285368	50.04
Totals					
		555618	100.00	26548678	100.00



Detector A (254nm) Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	17.867	14862	2.39	575780	1.83
2	24.043	606899	97.61	30967105	98.17
Totals					
		621761	100.00	31542885	100.00

<sup>1</sup>H and <sup>13</sup>C NMR of **3k** -3.268 -3.539 I ſſ MeQ `Ń CH₃ 5.5 5.5 1-00 5.0 **F60.6** - 3.5 0.974 2.004 1.05-I 1.99 2.05 신네 4.5 4.0 f1 (ppm) 7.0 8.5 8.0 7.5 6.5 6.0 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -171.875 -144.007 131.392 126.326 126.326 122.067 112.061 119.496 119.496 117.288 109.628 100.541 100.541 106.551 77414 76.991 -65.916 -65.916 56.498 55.594 -26.737 MeO `N ĊH₃ 0 90 fl (ppm) 180 160 110 100 80 70 60 40 10 170 150 140 130 120 50 30 20







Detector	
A (254nm)	

Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	17.493	15457	4.52	762876	3.70
2	25.483	326706	95.48	19876254	96.30
Totals					
		342163	100.00	20639130	100.00









Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	9.177	34742	3.38	765440	2.65
2	11.823	992645	96.62	28173253	97.35
Totals					
		1027387	100.00	28938693	100.00



![](_page_38_Figure_0.jpeg)

![](_page_38_Figure_1.jpeg)

![](_page_38_Figure_2.jpeg)

S38

![](_page_39_Figure_0.jpeg)

![](_page_40_Figure_0.jpeg)

![](_page_40_Figure_1.jpeg)

![](_page_40_Figure_2.jpeg)

![](_page_41_Figure_0.jpeg)

![](_page_42_Figure_0.jpeg)

![](_page_42_Figure_1.jpeg)

Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	11.657	17834	5.93	426408	5.31
2	12.550	158654	52.79	3800220	47.28
3	15.830	124067	41.28	3810451	47.41
Totals					
		300555	100.00	8037079	100.00

![](_page_42_Figure_4.jpeg)

Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	11.683	57399	7.34	1398149	7.30
2	12.553	699419	89.45	16985208	88.67
3	15.847	25133	3.21	771108	4.03
Totals					
		781951	100.00	19154465	100.00

![](_page_43_Figure_0.jpeg)

![](_page_44_Figure_0.jpeg)

![](_page_44_Figure_1.jpeg)

2	29.040	101633	48.41	5923586	50.03
Totals					
		209951	100.00	11839171	100.00

![](_page_44_Figure_3.jpeg)

			1 of conte		
1	26.333	27833	7.57	1547181	7.14
2	29.013	339613	92.43	20126573	92.86
Totals					
		367446	100.00	21673754	100.00

![](_page_45_Figure_0.jpeg)

![](_page_46_Figure_0.jpeg)

![](_page_46_Figure_1.jpeg)

Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	14.137	9902	3.42	305260	2.35
2	16.800	8787	3.03	316865	2.43
3	19.170	158956	54.90	6200399	47.64
4	26.747	111880	38.64	6192809	47.58
Totals					
		289525	100.00	13015333	100.00

![](_page_46_Figure_4.jpeg)

De	tector
A (	(254nm)

Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	14.207	10845	2.00	334073	1.57
2	16.907	7684	1.42	281256	1.33
3	19.253	509977	94.22	19899544	93.78
4	26.560	12767	2.36	703691	3.32
Totals					
		541273	100.00	21218564	100.00

![](_page_47_Figure_0.jpeg)

![](_page_48_Figure_0.jpeg)

![](_page_48_Figure_1.jpeg)

100.00

14802606

100.00

350598

![](_page_48_Figure_2.jpeg)

Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	17.073	990277	96.86	35970524	95.76
2	23.583	32107	3.14	1591970	4.24
Totals					
		1022384	100.00	37562494	100.00

![](_page_49_Figure_0.jpeg)

![](_page_50_Figure_0.jpeg)

![](_page_50_Figure_1.jpeg)

![](_page_50_Figure_2.jpeg)

![](_page_51_Figure_0.jpeg)

![](_page_52_Figure_0.jpeg)

![](_page_52_Figure_1.jpeg)

![](_page_52_Figure_2.jpeg)

Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	11.730	45090	6.28	1571833	5.35
2	14.453	672963	93.72	27804589	94.65
Totals					
		718053	100.00	29376422	100.00

![](_page_53_Figure_0.jpeg)

![](_page_53_Figure_1.jpeg)

![](_page_54_Figure_0.jpeg)

![](_page_54_Figure_1.jpeg)

A (254nm) Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	15.297	11803	3.09	386952	2.34
2	16.650	10111	2.65	355473	2.15
3	17.913	210791	55.25	7873439	47.70
4	25.127	148804	39.00	7890073	47.80
Totals					
		381509	100.00	16505937	100.00

![](_page_54_Figure_3.jpeg)

Pk #	Retention Time	Height	Height	Area	Area Percent
			Percent		
1	15.303	10712	1.41	347173	1.21
2	16.657	10615	1.40	367877	1.28
3	17.907	714971	94.20	26905020	93.40
4	24.913	22699	2.99	1186539	4.12
Totals					
		758997	100.00	28806609	100.00

![](_page_55_Figure_0.jpeg)

![](_page_56_Figure_0.jpeg)

![](_page_56_Figure_1.jpeg)

![](_page_56_Figure_2.jpeg)

A (254nm) Pk #	Retention Time	Height	Height Percent	Area	Area Percent
1	16.350	13321	2.33	473417	1.69
2	19.053	7374	1.29	297306	1.06
3	24.177	540098	94.49	26536537	94.79
4	32.607	10804	1.89	689009	2.46
Totals					
		571597	100.00	27996269	100.00

![](_page_57_Figure_0.jpeg)

![](_page_58_Figure_0.jpeg)

![](_page_58_Figure_1.jpeg)

1 Det.A Ch1 / 254nm

Detector A	Detector A Ch1 254nm					
Peak#	Ret. Time	Area	Height	Area %	Height %	
1	6.392	260715	24996	4.449	6.379	
2	6.625	293307	24620	5.005	6.283	
3	8.248	2648791	180871	45.199	46.157	
4	9.222	2657527	161373	45.348	41.181	
Total		5860339	391860	100.000	100.000	

![](_page_58_Figure_4.jpeg)

1 Det.A Ch1 / 254nm

D	etector A	Ch1 254nm				
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	6.409	157238	17170	1.598	2.471
	2	6.645	554549	48677	5.637	7.005
	3	8.267	8887906	614115	90.348	88.371
	4	9.245	237699	14966	2.416	2.154
	Total		9837392	694928	100.000	100.000

![](_page_59_Figure_0.jpeg)

![](_page_60_Figure_0.jpeg)

![](_page_60_Figure_1.jpeg)

1 Det.A Ch1/254nm

PeakTable

Detector A Ch1 254nm					
Peak#	Ret. Time	Area	Height	Area %	
1	14.761	4649797	172968	49.909	
2	16.033	4666710	157077	50.091	
Total		9316507		100.000	

![](_page_60_Figure_5.jpeg)

1 Det.A Ch1/254nm

PeakTable

		1 00011 000		
Detector A	Ch1 254nm			
Peak#	Ret. Time	Area	Height	Area %
1	14.738	14422183	498098	97.074
2	16.078	434643	15095	2.926
Total		14856826		100.000

![](_page_61_Figure_0.jpeg)

S61

![](_page_62_Figure_0.jpeg)

![](_page_62_Figure_1.jpeg)

![](_page_62_Figure_2.jpeg)

PeakTable

Detector A	Ch1 254nm			
Peak#	Ret. Time	Area	Height	Area %
1	8.249	535521	27622	3.109
2	8.788	553175	25930	3.211
3	10.690	8051627	295211	46.740
4	13.502	8086125	265367	46.940
Total		17226449		100.000

![](_page_62_Figure_5.jpeg)

1 Det.A Ch1/254nm

----

PeakTable

Detector A	Detector A Ch1 254nm				
Peak#	Ret. Time	Area	Height	Area %	
1	8.243	346029	20998	2.423	
2	8.777	188230	10196	1.318	
3	10.676	13354315	545847	93.524	
4	13.565	390483	14520	2.735	
Total		14279057		100.000	

![](_page_63_Figure_0.jpeg)

![](_page_64_Figure_0.jpeg)

![](_page_64_Figure_1.jpeg)

1 Det.A Ch1 / 254nm

Detector A	Ch1 254nm				
Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.055	105199	7997	3.544	6.593
2	8.460	104583	6393	3.523	5.270
3	10.723	1385839	65217	46.684	53.763
4	15.910	1372943	41698	46.249	34.374
Total		2968564	121304	100.000	100.000

![](_page_64_Figure_4.jpeg)

1 Det.A Ch1 / 254nm

Detector A	Ch1 254nm				
Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.036	127842	9302	4.028	8.802
2	8.435	68476	4251	2.157	4.023
3	10.703	89068	4214	2.806	3.988
4	15.827	2888582	87914	91.009	83.188
Tota	1	3173968	105682	100.000	100.000

![](_page_65_Figure_0.jpeg)

![](_page_66_Figure_0.jpeg)

![](_page_66_Figure_1.jpeg)

1 Det.A Ch1/254nm

PeakTable

0.0

Detector A	Ch1 254nm			
Peak#	Ret. Time	Area	Height	Area %
1	23.204	3718546	50052	42.410
2	25.817	739130	8375	8.430
3	29.126	546885	5859	6.237
4	62.384	3763460	16515	42.923
Total		8768022		100.000
	1	1		1

![](_page_66_Figure_5.jpeg)

1 Det.A	Ch1/254nm
---------	-----------

_		_		
Daa	-	Col	h	
Pea	κ.	12	D	Ie.
_			~,	

Detector A	Ch1 254nm			
Peak#	Ret. Time	Area	Height	Area %
1	23.128	3664641	48459	45.753
2	25.786	1328417	14588	16.585
3	29.099	1238017	12330	15.457
4	63.007	1778488	8094	22.205
Total		8009564		100.000

![](_page_67_Figure_0.jpeg)

### S67

![](_page_68_Figure_0.jpeg)

![](_page_68_Figure_1.jpeg)

1 Det.A Ch1/254nm

T

PeakTable

Detector A	Ch1 254nm			
Peak#	Ret. Time	Area	Height	Area %
1	10.010	3659829	145910	49.616
2	14.400	3716482	112451	50.384
Total		7376311		100.000

![](_page_68_Figure_5.jpeg)

1 Det.A Ch1/254nm

PeakTable

Detector A Ch1 254nm						
Peak#	Ret. Time	Area	Height	Area %		
1	9.961	9354308	328945	85.298		
2	14.068	1612293	50295	14.702		
Total		10966602		100.000		

![](_page_69_Figure_0.jpeg)

S69

![](_page_70_Figure_0.jpeg)

![](_page_70_Figure_1.jpeg)

1 Det.A Ch1/254nm

PeakTable

		I Cak I au		
Detector A	Ch1 254nm			
Peak#	Ret. Time	Area	Height	Area %
1	17.378	3206948	95401	49.625
2	18.757	3255448	85804	50.375
Total		6462397		100.000

![](_page_70_Figure_5.jpeg)

1 Det.A Ch1/254nm

PeakTable

		I Cak I au		
Detector A	Ch1 254nm			
Peak#	Ret. Time	Area	Height	Area %
1	17.416	5362148	140368	49.740
2	18.807	5418267	135087	50.260
Total		10780415		100.000